Chemed Q3 2026 Revenue Up 10.6%
Chemed boosted revenue and EPS in Q3 2026, driven by growth in its VITAS Hospice segment despite challenges at Roto-Rooter.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed